Myriad Genetics, Inc. (NASDAQ: MYGN) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $531M. The Maz Rating grades it against the other companies in its sector.
Myriad Genetics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.54, Myriad Genetics, Inc. trades at 0.7x sales and 2.0x book value. Over the last twelve months it generated about $806M of revenue and a net loss of $131M. It runs a gross margin of 68.3%, an operating margin of -14.3% and a net margin of -16.1%. It shows return on equity of -40.4%, return on invested capital of -24.0% and a free cash flow yield of -6.6%. On the balance sheet: a debt-to-equity ratio of 0.78 and a current ratio of 1.98. Over the past 52 weeks the share price ranged from $2.74 to $8.09, with a beta of 1.61.
Myriad Genetics, Inc. does not currently pay a dividend.
37 Wall Street analyst ratings cover the stock: 8 Buy, 22 Hold and 7 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.